CCM
AXSM icon

Cutter Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Cutter Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,767
Closed -$9.51M – 25
2024
Q3 		$9.51M Buy
+105,767
New +$9.23M 2.81% 17

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutter Capital Management's AXSM Position: Q4 2024 in Review

Cutter Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 105,767 shares — an estimated $9.51M sold.

Cutter Capital Management first reported a position in AXSM in Q3 2024 and held it in 1 quarter. The position peaked at $9.51M in Q3 2024. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • Cutter Capital Management reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cutter Capital Management sold 105,767 Axsome Therapeutics shares in Q4 2024, an estimated $9.51M.
  • Cutter Capital Management first reported a position in Axsome Therapeutics in Q3 2024 and held it in 1 quarter.
  • Cutter Capital Management's Axsome Therapeutics position peaked at $9.51M in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on Cutter Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.